Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Editas Medicine, Inc.    EDIT

EDITAS MEDICINE, INC.

(EDIT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société EDITAS MEDICINE, INC.
11/10EDITAS MEDICINE : Reports Inducement Grants to New Chief Medical Officer
AQ
11/10Editas Medicine Reports Inducement Grants to New Chief Medical Officer
GL
11/09EDITAS MEDICINE : to Present at Barclays Gene Editing & Gene Therapy Summit
AQ
11/09Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit
GL
11/09EDITAS MEDICINE : Appoints Lisa A. Michaels, M.D., as Chief Medical Officer
AQ
11/09Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer
GL
11/06EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..
AQ
11/05EDITAS : 3Q Earnings Snapshot
AQ
11/05EDITAS MEDICINE, INC. : Results of Operations and Financial Condition, Financial..
AQ
11/05EDITAS MEDICINE : November 2020 Corporate Presentation
PU
11/05EDITAS MEDICINE : Announces Third Quarter 2020 Results and Update
AQ
11/05Editas Medicine Announces Third Quarter 2020 Results and Update
GL
10/29EDITAS MEDICINE : to Host Conference Call Discussing Third Quarter 2020 Results ..
AQ
10/29Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results..
GL
10/01EDITAS MEDICINE : October 2020 Corporate Presentation
PU
10/01EDITAS MEDICINE : to Participate in Upcoming Investor Conference
AQ
10/01Editas Medicine to Participate in Upcoming Investor Conference
GL
09/11EDITAS MEDICINE : Announces U.S. Patent and Trademark Office Grants the Broad In..
AQ
09/11Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad I..
GL
09/09EDITAS MEDICINE : September 2020 Corporate Presentation
PU
09/04Editas Medicine to Participate in Upcoming Investor Conferences
GL
08/24Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for ..
GL
08/07EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..
AQ
08/07EDITAS : 2Q Earnings Snapshot
AQ
08/06EDITAS MEDICINE, INC. : Entry into a Material Definitive Agreement, Termination ..
AQ
08/06Editas Medicine Announces Second Quarter 2020 Results and Update
GL
08/06Editas Medicine Regains Full Global Rights to Ocular Medicines
GL
07/29Catalent Enters into Strategic Partnership with Editas Medicine to Support Ge..
GL
07/27Editas Medicine Appoints Gad Berdugo as Chief Business Officer
GL
07/23Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Result..
GL
07/07Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 ..
GL
06/26EDITAS MEDICINE : Announces Closing of Offering of Common Stock and Full Exercis..
AQ
06/25EDITAS MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events..
AQ
06/23EDITAS MEDICINE : Announces Pricing of Offering of Common Stock
AQ
06/23EDITAS MEDICINE : Announces Offering of Common Stock
AQ
06/15EDITAS MEDICINE, INC. : Submission of Matters to a Vote of Security Holders (for..
AQ
06/12Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sick..
GL
05/15EDITAS MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial St..
AQ
05/15Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12..
GL
05/08EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..
AQ
05/07EDITAS : 1Q Earnings Snapshot
AQ
05/07EDITAS MEDICINE, INC. : Results of Operations and Financial Condition, Financial..
AQ
05/07Editas Medicine Announces First Quarter 2020 Results and Update
GL
04/30Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results..
GL
04/29Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic..
GL
03/04EDITAS MEDICINE : March 2020 Corporate Presentation
PU
03/04Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Pha..
GL
02/26EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition an..
AQ
02/26EDITAS MEDICINE, INC. : Results of Operations and Financial Condition, Financial..
AQ
02/26EDITAS : 4Q Earnings Snapshot
AQ
02/26Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Updat..
GL
02/19Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Ye..
GL
01/13Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conferen..
GL
01/13Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Dev..
GL
01/10Editas Medicine Reports Inducement Grants to New Chief Financial Officer
GL
01/09Editas Medicine Strengthens Executive Leadership Team to Support Long-term Gr..
GL
01/02Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conferen..
GL
2019Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Deve..
GL
2019Editas Medicine Announces Third Quarter 2019 Results and Update
GL
2019Editas Medicine and Celgene Corporation Amend Existing Collaboration to Devel..
GL
2019Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results..
GL
2019Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
GL
2019Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore ..
GL
2019EDITAS MEDICINE : A statement of beneficial ownership of common stock by certain..
PU
2019EDITAS MEDICINE : October 2019 Corporate Presentation
PU
2019Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreemen..
GL
2019Editas Medicine to Participate in Upcoming Investor Conferences
GL
2019Editas Medicine Announces Second Quarter 2019 Results and Update
GL
2019Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Result..
GL
2019Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disea..
GL
2019Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results..
GL
2019Allergan and Editas Medicine Announce Initial Data from Natural History Study..
GL
2019Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Updat..
GL
2019Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Ye..
GL
2019Editas Medicine Names David Scadden, M.D., to Board of Directors
GL
1  2  3Next
Upcoming event on EDITAS MEDICINE, INC.